Development of Dual Practical Manufacturing Routes to Cognate Pyrrolobenzodiazepine-Based Linker-Drugs-Reference-Cited by-同舟云学术

Development of Dual Practical Manufacturing Routes to Cognate Pyrrolobenzodiazepine-Based Linker-Drugs

Published:2022-08-08 Issue:8 Volume:26 Page:2155-2175
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Koenig Stefan G.¹^ORCID,Angelaud Rémy¹,Crittenden Christopher M.²,Kurita Kenji²,Russell David J.²,Marcoux Jean-Francois³,Matt Thomas⁴,Gosselin Francis¹^ORCID

Affiliation:

1. Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. Department of Small Molecule Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

3. Department of Manufacturing and Science Technology, F. Hoffmann-La Roche Ltd, Viaduktstrasse 31, 4051 Basel, Switzerland

4. Chemical R&D Department, Cerbios Pharma SA, Via Figino 6, 6917 Barbengo/Lugano, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00129

Reference29 articles.

1. Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines

2. From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)

3. Design, Synthesis, and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity

4. The Pyrrolobenzodiazepine Dimer SJG-136 Forms Sequence-Dependent Intrastrand DNA Cross-Links and Monoalkylated Adducts in Addition to Interstrand Cross-Links

5. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates